- Home
- MQY vs ANAB Comparison
MQY vs ANAB Comparison
Compare MQY & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MQY
- ANAB
- Stock Information
- Founded
- MQY 1994
- ANAB 2005
- Country
- MQY United States
- ANAB United States
- Employees
- MQY N/A
- ANAB N/A
- Industry
- MQY Investment Bankers/Brokers/Service
- ANAB Biotechnology: Pharmaceutical Preparations
- Sector
- MQY Finance
- ANAB Health Care
- Exchange
- MQY Nasdaq
- ANAB Nasdaq
- Market Cap
- MQY 784.4M
- ANAB 759.5M
- IPO Year
- MQY N/A
- ANAB 2017
- Fundamental
- Price
- MQY $11.20
- ANAB $19.28
- Analyst Decision
- MQY
- ANAB Buy
- Analyst Count
- MQY 0
- ANAB 10
- Target Price
- MQY N/A
- ANAB $37.75
- AVG Volume (30 Days)
- MQY 184.8K
- ANAB 552.2K
- Earning Date
- MQY 01-01-0001
- ANAB 05-05-2025
- Dividend Yield
- MQY 4.73%
- ANAB N/A
- EPS Growth
- MQY N/A
- ANAB N/A
- EPS
- MQY N/A
- ANAB N/A
- Revenue
- MQY N/A
- ANAB $111,872,000.00
- Revenue This Year
- MQY N/A
- ANAB N/A
- Revenue Next Year
- MQY N/A
- ANAB $35.66
- P/E Ratio
- MQY N/A
- ANAB N/A
- Revenue Growth
- MQY N/A
- ANAB 387.20
- 52 Week Low
- MQY $9.82
- ANAB $12.21
- 52 Week High
- MQY $12.52
- ANAB $41.31
- Technical
- Relative Strength Index (RSI)
- MQY 52.84
- ANAB 55.52
- Support Level
- MQY $11.22
- ANAB $18.51
- Resistance Level
- MQY $11.43
- ANAB $21.14
- Average True Range (ATR)
- MQY 0.11
- ANAB 1.13
- MACD
- MQY 0.05
- ANAB -0.20
- Stochastic Oscillator
- MQY 64.92
- ANAB 50.19
About MQY Blackrock MuniYield Quality Fund Inc.
Blackrock Muniyield Quality Fund Inc is a closed-end management investment company. The company's objective is to provide shareholders with as high a level of current income exempt from U.S. federal income taxes as is consistent with its investment policies and prudent investment management. The company invests in Transportation, Corporate, Health, Utilities, Education, Housing, and other sectors.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).